| Mrs Glorivee Cortes, RPH | |
|
59 Calle Daguey, Anasco, PR 00610-2602 | |
| (787) 229-1313 | |
| (787) 826-7384 |
| Full Name | Mrs Glorivee Cortes |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 59 Calle Daguey, Anasco, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346249687 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 4712 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Glorivee Cortes, RPH Hc 6 Box 67554, Aguadilla, PR 00603-9856 Ph: (787) 891-9044 | Mrs Glorivee Cortes, RPH 59 Calle Daguey, Anasco, PR 00610-2602 Ph: (787) 229-1313 |
News Archive
A study analysing the positive and negative effects of energy drinks on athletes has seen that, although in principle their sports performance was seen to improve by between 3% and 7%, there was also an increase in the frequency of insomnia, nervousness and the level of stimulation in the hours following competition.
Scientists at Osel Inc. and the National Cancer Institute (NCI) have developed a new way to prevent HIV infection by genetically enhancing the ability of naturally occurring vaginal bacteria to block viral transmission.
The U.S. Food and Drug Administration has announced it will require the manufacturers of antiepileptic drugs to add to these products' prescribing information, or labeling, a warning that their use increases risk of suicidal thoughts and behaviors (suicidality). The action includes all antiepileptic drugs including those used to treat psychiatric disorders, migraine headaches and other conditions, as well as epilepsy.
The National Comprehensive Cancer Network Oncology Research Program has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in solid tumors, including bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.
The U.S. Food and Drug Administration today approved Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.
› Verified 3 days ago
Dr. Maryelis Gonzalez, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Carr 402, Anasco, PR 00610 Phone: 787-229-1150 Fax: 787-229-1160 | |
Eydia S Barreto Perez, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Calle 65 De Infanteria #68, Anasco, PR 00610 Phone: 787-826-2390 | |
Cristina Irais Gonzalez Rivera, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Carr. 402 Km 1.8, Bo. Marias, Zona Industrial, Anasco, PR 00610 Phone: 787-229-1515 Fax: 787-229-1516 | |
Dr. Randy Omar Rivera Aviles, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 17 Calle San Antonio, Anasco, PR 00610 Phone: 787-826-4400 | |
Mrs. Dorothy E Rosario Hoke, RPHA PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 402 Road Km 2, Centro Comercial Feliberti, Anasco, PR 00610 Phone: 787-826-8888 Fax: 787-826-7777 | |
Lizeyda Nieves, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Pr 2 & Pr 402, Anasco, PR 00610 Phone: 787-826-1092 Fax: 787-826-2333 | |
Dr. Lesley Arcelay Feliciano, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Carr 402 Km 2.9 Bo Quebrada Larga, Anasco, PR 00610 Phone: 787-826-8888 |